132.82
price up icon1.48%   1.94
 
loading
前日終値:
$130.88
開ける:
$131.91
24時間の取引高:
9.80M
Relative Volume:
1.45
時価総額:
$223.47B
収益:
$42.34B
当期純損益:
$13.50B
株価収益率:
17.23
EPS:
7.71
ネットキャッシュフロー:
$6.66B
1週間 パフォーマンス:
+3.08%
1か月 パフォーマンス:
+0.67%
6か月 パフォーマンス:
+11.99%
1年 パフォーマンス:
+25.40%
1日の値動き範囲:
Value
$131.33
$136.80
1週間の範囲:
Value
$128.00
$136.80
52週間の値動き範囲:
Value
$99.71
$140.84

Abbott Laboratories Stock (ABT) Company Profile

Name
名前
Abbott Laboratories
Name
セクター
Healthcare (1152)
Name
電話
(224) 667-6100
Name
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
職員
114,000
Name
Twitter
@AbbottNews
Name
次回の収益日
2025-04-16
Name
最新のSEC提出書
Name
ABT's Discussions on Twitter

ABT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Medical Devices icon
ABT
Abbott Laboratories
132.82 223.47B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
104.93 150.72B 17.55B 2.03B 2.37B 1.37
Medical Devices icon
SYK
Stryker Corp
378.22 139.34B 22.60B 2.99B 3.49B 7.76
Medical Devices icon
MDT
Medtronic Plc
84.85 107.15B 33.20B 4.26B 5.47B 3.29
Medical Devices icon
EW
Edwards Lifesciences Corp
75.65 44.54B 5.54B 4.18B 259.90M 7.00

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-08 開始されました Oppenheimer Outperform
2024-09-19 開始されました Piper Sandler Overweight
2024-07-30 ダウングレード Edward Jones Buy → Hold
2024-05-30 開始されました Goldman Buy
2023-07-21 アップグレード Wolfe Research Underperform → Peer Perform
2023-05-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-04-20 繰り返されました Barclays Overweight
2023-04-20 繰り返されました Bernstein Outperform
2023-04-20 繰り返されました JP Morgan Overweight
2023-04-20 繰り返されました Raymond James Outperform
2023-04-20 繰り返されました UBS Buy
2023-04-20 繰り返されました Wolfe Research Underperform
2023-03-29 開始されました UBS Buy
2022-10-26 開始されました Mizuho Neutral
2022-10-18 開始されました Barclays Overweight
2022-10-12 開始されました Jefferies Hold
2022-07-06 開始されました Wolfe Research Underperform
2022-03-02 再開されました BofA Securities Buy
2022-01-27 繰り返されました Credit Suisse Outperform
2022-01-27 繰り返されました Morgan Stanley Overweight
2022-01-27 繰り返されました Raymond James Outperform
2022-01-27 繰り返されました UBS Buy
2021-12-10 開始されました RBC Capital Mkts Outperform
2021-10-27 アップグレード Atlantic Equities Neutral → Overweight
2021-10-14 開始されました Redburn Neutral
2021-05-25 開始されました Barclays Overweight
2021-04-15 開始されました Atlantic Equities Neutral
2021-01-28 アップグレード BTIG Research Neutral → Buy
2020-09-11 開始されました Wolfe Research Outperform
2020-06-01 ダウングレード Goldman Neutral → Sell
2020-03-05 開始されました Citigroup Buy
2020-02-13 開始されました Goldman Neutral
2020-02-06 再開されました BTIG Research Neutral
2020-01-02 ダウングレード Guggenheim Buy → Neutral
2019-06-13 繰り返されました BofA/Merrill Buy
2019-02-07 繰り返されました BofA/Merrill Buy
2019-01-02 ダウングレード Citigroup Neutral → Sell
2018-11-30 アップグレード Goldman Neutral → Buy
2018-10-16 開始されました Barclays Overweight
2018-06-27 開始されました Bernstein Outperform
2018-01-30 繰り返されました Citigroup Neutral
2018-01-25 繰り返されました Stifel Buy
2018-01-25 アップグレード William Blair Mkt Perform → Outperform
2018-01-03 開始されました Evercore ISI Outperform
2018-01-02 アップグレード JP Morgan Neutral → Overweight
2018-01-02 アップグレード Morgan Stanley Equal-Weight → Overweight
2017-10-19 繰り返されました RBC Capital Mkts Outperform
2017-10-19 繰り返されました Stifel Buy
すべてを表示

Abbott Laboratories (ABT) 最新ニュース

pulisher
10:55 AM

Abbott (ABT) Launches Rapid Concussion Test with MotoAmerica - GuruFocus

10:55 AM
pulisher
08:20 AM

2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio? - The Motley Fool

08:20 AM
pulisher
May 02, 2025

Abbott Laboratories Director Makes Significant Stock Sale! - TipRanks

May 02, 2025
pulisher
May 02, 2025

Abbott Beats Bellwether In Formula MDL Ahead Of Trial - Law360

May 02, 2025
pulisher
May 02, 2025

US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease - Reuters

May 02, 2025
pulisher
May 02, 2025

Abbott Laboratories (ABT) Sees Stock Rise Following Favorable Court Ruling - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Abbott gains after upcoming baby formula case thrown out (ABT:NYSE) - Seeking Alpha

May 02, 2025
pulisher
May 02, 2025

Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st

May 02, 2025
pulisher
May 02, 2025

Stroke Management Market Is Booming Worldwide | Abbott - openPR.com

May 02, 2025
pulisher
May 02, 2025

Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Abbott Laboratories Announces Executive Vice President’s Retirement - TipRanks

May 01, 2025
pulisher
May 01, 2025

MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races - Stock Titan

May 01, 2025
pulisher
May 01, 2025

Abbott Laboratories (ABT): Among the Best Stocks to Buy During Recession - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Abbott Laboratories price tries to shake off negative pressureForecast today01-05-2025 - Economies.com

May 01, 2025
pulisher
May 01, 2025

MotoAmerica: More On Abbott Blood Test for Rapid Concussion Evaluation On-Site - Roadracing World

May 01, 2025
pulisher
Apr 30, 2025

Abbott Laboratories (ABT): Jim Cramer Calls It a ‘Tour de Force’ — Why He’s Still Amazed at This Stock - Yahoo Finance

Apr 30, 2025
pulisher
Apr 29, 2025

Abbott Laboratories (ABT) Announces Results of Annual Shareholders Meeting - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Abbott (ABT) Integrates Libre CGM Data with Epic's Health Records - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Abbott signs deal with Epic for CGM data integration (ABT:NYSE) - Seeking Alpha

Apr 29, 2025
pulisher
Apr 29, 2025

Abbott Integrates Libre CGM’s Data with Epic’s EHR System - Medical Product Outsourcing

Apr 29, 2025
pulisher
Apr 29, 2025

Abbott (ABT) Teams Up with Epic for Advanced Health Data Integra - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Abbott integrates Libre CGM data into Epic EHR workflows - Drug Delivery Business

Apr 29, 2025
pulisher
Apr 29, 2025

Abbott Partners With Epic to Transform Diabetes Care for 280M Patients | ABT Stock News - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Sevoflurane Market Overall Study Report 2025-2032 | Abbott Laboratories, Baxter, Piramal Pharma Solutions - openPR.com

Apr 29, 2025
pulisher
Apr 28, 2025

A Look Into Abbott Laboratories Inc's Price Over Earnings - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials - simplywall.st

Apr 28, 2025
pulisher
Apr 28, 2025

Abbott (ABT) Unveils Promising Results from Leadless Pacemaker S - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Yahoo Finance

Apr 28, 2025
pulisher
Apr 28, 2025

Drug Eluting Stents Market Overall Study Report 2025-2032 | - openPR.com

Apr 28, 2025
pulisher
Apr 28, 2025

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price - Yahoo Finance

Apr 28, 2025
pulisher
Apr 28, 2025

Abbott Laboratories Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - simplywall.st

Apr 28, 2025
pulisher
Apr 28, 2025

The health care sector is a mixed picture, but Abbott Labs is a buy. - Forbes

Apr 28, 2025
pulisher
Apr 28, 2025

Abbott Stuns with Study Results in PFA Market: Is It Enough? - Medical Device and Diagnostic industry

Apr 28, 2025
pulisher
Apr 28, 2025

Pesticides Market to Experience Rapid Growth Driven by Abbott - openPR.com

Apr 28, 2025
pulisher
Apr 28, 2025

Abbott Laboratories Says Investigational Pacemaker Shows Safety, Performance - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

India Medical Nutrition Market Overall Study Report 2025-2032 | - openPR.com

Apr 28, 2025
pulisher
Apr 28, 2025

Abbott has positive study results for Aveir CSP leadless pacemaker - MassDevice

Apr 28, 2025
pulisher
Apr 27, 2025

Abbott Laboratories: Strategic Advancements and Market Positioning with Volt PFA Platform Drive Buy Rating - TipRanks

Apr 27, 2025
pulisher
Apr 27, 2025

Abbott announces new data from its Volt CE Mark Study - TipRanks

Apr 27, 2025
pulisher
Apr 27, 2025

Breakthrough Heart Technology: Abbott's Leadless Pacemaker Trial Success Launches Major Global Study - Stock Titan

Apr 27, 2025
pulisher
Apr 26, 2025

New data supports Abbott Volt pulsed field ablation system - MassDevice

Apr 26, 2025
pulisher
Apr 26, 2025

Abbott Laboratories Says New Clinical Study Data Showcase Long-Term, Sustained Benefits Of Abbott's Volt(TM) Pfa System For Patients With Afib - marketscreener.com

Apr 26, 2025
pulisher
Apr 26, 2025

Abbott's Revolutionary AFib Treatment Achieves 83.5% Freedom from Arrhythmia in Landmark Study - Stock Titan

Apr 26, 2025
pulisher
Apr 26, 2025

FDA says recall of Abbott HeartMate power unit is serious - MassDevice

Apr 26, 2025
pulisher
Apr 25, 2025

FDA announces new recall of Abbott heart pump accessories over significant safety risks - Cardiovascular Business

Apr 25, 2025
pulisher
Apr 25, 2025

Clinical Diagnostics Market: Trends, Growth, and Key Players - openPR.com

Apr 25, 2025
pulisher
Apr 24, 2025

Medtronic seeks FDA nod for insulin pump (MDT:NYSE) - Seeking Alpha

Apr 24, 2025
pulisher
Apr 24, 2025

EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

June 6th Options Now Available For Abbott Laboratories (ABT) - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction - Yahoo Finance

Apr 24, 2025
pulisher
Apr 23, 2025

Top Analyst Reports for Coca-Cola, Abbott & RTX - Yahoo Finance

Apr 23, 2025

Abbott Laboratories (ABT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
medical_devices BSX
$104.93
price up icon 1.69%
medical_devices SYK
$378.22
price up icon 1.13%
medical_devices MDT
$84.85
price up icon 1.54%
medical_devices EW
$75.65
price up icon 0.63%
$70.53
price up icon 4.23%
大文字化:     |  ボリューム (24 時間):